What Lurks Inside the Covid Vax? By Brian Simpson
Various chemicals have been added to the Covid vaxxes to improve their efficacy, and one such chemical goes by the intimidating name of N1-methyl-pseudouridine. For our purposes it does not matter exactly what this is, as I don't know either, but the chemical now has safety concerns, including affecting those aspects of the immune system for fighting cancer, and since the vax rollout, cancers have been on the rise, especially the turbo-charged variety.
According to the article: "Based on this compelling evidence, we suggest that future clinical trials for cancers or infectious diseases should not use mRNA vaccines with a 100 % m1Ψ [N1-methyl-pseudouridine] modification, but rather ones with the lower percentage of m1Ψ modification to avoid immune suppression." That is, less of the stuff, in the hope that nothing bad happens.
As will be detailed in another article at the blog today, the deadly truth about the vaxxes is slowly seeping out, like waste from a decaying bin.
"A comprehensive review by an international consortium of scientists has raised serious concerns about the COVID-19 mRNA vaccines' safety profile.
Review articles are summaries of current research on a particular topic. They are also sometimes called literature reviews or secondary sources.
The review, "N1-methyl-pseudouridine (m1Ψ): Friend or foe of cancer?" published on Science Direct, delves into the potential implications of a vaccine ingredient—N1-methyl-pseudouridine (m1Ψ)—that may play a role in immune suppression and cancer proliferation.
m1Ψ was incorporated into Pfizer-BioNTech's COVID-19 mRNA vaccine to enhance its efficacy.
This component was introduced in the mRNA vaccine as a means to produce a significant amount of modified SARS-CoV-2 spike mRNA through in vitro transcription (IVT). This modification was crucial in the rapid development and deployment of the vaccine during the height of the pandemic.
However, the review article calls into question the long-term impacts of this modification, especially concerning the vaccine's interaction with the body's immune response and potential carcinogenic effects.
According to the review's abstract, evidence suggests that while mRNA vaccines may have been "effective" in reducing severe disease outcomes, they might not provide sterilizing immunity, leaving individuals susceptible to recurring infections.
More critically, the review highlights that the inclusion of m1Ψ in mRNA vaccines appears to inhibit key immunological pathways, impairing the body's early interferon signaling.
Interferon is a natural substance that helps the body's immune system fight infection and other diseases, such as cancer.
This immunosuppression, intended to ensure efficient synthesis of the spike protein and minimize immune activation, may inadvertently foster an environment conducive to cancer development and metastasis.
In contrast, mRNA vaccines without this modification have shown the opposite effect.
"Based on this compelling evidence, we suggest that future clinical trials for cancers or infectious diseases should not use mRNA vaccines with a 100 % m1Ψ modification, but rather ones with the lower percentage of m1Ψ modification to avoid immune suppression," the researchers said.
https://www.sciencedirect.com/science/article/pii/S0141813024022323
Abstract
Due to the health emergency created by SARS-CoV-2, the virus that causes the COVID-19 disease, the rapid implementation of a new vaccine technology was necessary. mRNA vaccines, being one of the cutting-edge new technologies, attracted significant interest and offered a lot of hope. The potential of these vaccines in preventing admission to hospitals and serious illness in people with comorbidities has recently been called into question due to the vaccines' rapidly waning immunity. Mounting evidence indicates that these vaccines, like many others, do not generate sterilizing immunity, leaving people vulnerable to recurrent infections. Additionally, it has been discovered that the mRNA vaccines inhibit essential immunological pathways, thus impairing early interferon signaling. Within the framework of COVID-19 vaccination, this inhibition ensures an appropriate spike protein synthesis and a reduced immune activation. Evidence is provided that adding 100 % of N1-methyl-pseudouridine (m1Ψ) to the mRNA vaccine in a melanoma model stimulated cancer growth and metastasis, while non-modified mRNA vaccines induced opposite results, thus suggesting that COVID-19 mRNA vaccines could aid cancer development. Based on this compelling evidence, we suggest that future clinical trials for cancers or infectious diseases should not use mRNA vaccines with a 100 % m1Ψ modification, but rather ones with the lower percentage of m1Ψ modification to avoid immune suppression."
Comments